Abel Hall LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Abel Hall LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 11,340 shares of the biopharmaceutical company’s stock, valued at approximately $326,000.

Other institutional investors have also modified their holdings of the company. Clifford Swan Investment Counsel LLC boosted its holdings in shares of Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after buying an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Pfizer in the 4th quarter worth approximately $16,166,000. Finally, KLCM Advisors Inc. boosted its stake in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after purchasing an additional 74,487 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $35.86.

Pfizer Stock Performance

NYSE:PFE traded down $0.12 on Friday, reaching $27.53. 29,461,921 shares of the company’s stock were exchanged, compared to its average volume of 32,712,070. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $27.56 and a 200-day moving average of $27.78. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.36.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the company earned $1.23 earnings per share. The company’s revenue was down 19.5% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.10%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.